The U.S. Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide ...

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, hypertension, and cardiovascular disease.

The analysis found that while the amount of weight regain varies by drug, there is a consistent pattern of rapid weight ...

Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance coverage has fueled a risky but growing “gray” market for purchasing active ...

A new study in mice shows that tirzepatide—the active ingredient in the popular drugs Mounjaro and Zepbound—not only helps shed pounds but may also slow or reduce the growth of breast cancer tumors ...

A retrospective cohort study found that semaglutide and tirzepatide are linked with significantly lower risks of dementia and ...

Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...

Explore how semaglutide and tirzepatide may protect against dementia and stroke—keep reading for clinical implications and evidence.

Drugs like Ozempic and Mounjaro are becoming increasingly popular for treating obesity and type 2 diabetes. These medications ...

Key Points It isn't easy finding high-yield dividend growth stocks when the market is at an all-time high.Shares of Novo ...

Weight-loss drugs like semaglutide and tirzepatide may help shrink waistlines, but new research shows they fail to boost ...

Patients put on weight loss drugs like Ozempic and Wegovy may start regaining weight within weeks of discontinuing them, a ...